Less Expensive Inhaler Now AvailableMarch 5th, 2018 | Network News•News•Pharmacy Pearls
Opportunity to offer a less expensive generic maintenance inhaler to patients: The first generic ICS/LABA inhaler, fluticasone/salmeterol RespiClick®, was FDA approved in 2017. Current review of inhaler prescribing suggests the potential to realize a minimum of $900,000 savings across the network in 2018 by switching 25% of brand ICS/LABA inhalers to the generic product. Additionally, the lower estimated cash price ($10 with coupon to $94 without) coupled with broad coverage across most insurers, has resulted in substantially lower out of pocket costs for patients switched to date.
As of 4/1/2018, Excellus Medicaid Managed care is mandating patients currently prescribed Advair Diskus® or HFA® inhalers be switched. Excellus mailed communications to patients and providers impacted by this change. AHP is preparing a list of Commercial patients who may benefit financially from switching to the generic inhaler; we will forward this information as it becomes available.
Guidance on how to switch patients from other ICS/LABA inhalers to fluticasone/salmeterol RespiClick® can be found in this month’s installment of Pharmacy Pearls below:
March 2018 - asthma